Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

It was originally hoped that the presence of mutations in KRAS and other related genes would provide an easy answer as to whether to administer anti-EGFR antibody therapy to a given metastatic colorectal cancer patient. However, in nature nothing is simple, and there are a number of issues that practicing clinicians should be made aware of.

Original languageEnglish (US)
JournalONCOLOGY (United States)
Volume28
Issue number2
StatePublished - Feb 15 2014
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond'. Together they form a unique fingerprint.

Cite this